Trials / Recruiting
RecruitingNCT07044271
A Study of Multiple Olomorasib (LY3537982) Capsules in Healthy Participants
An Open-Label, Randomized, 3-Way Crossover Study Comparing the Pharmacokinetics of Multiple Olomorasib (LY3537982) Capsules
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 120 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to measure how much olomorasib gets into the bloodstream and how long it takes the body to get rid of it. Healthy participants will take olomorasib by mouth. The study will last about 7 weeks and will include 10 back-to-back overnight stays in the research center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olomorasib | Single dose |
Timeline
- Start date
- 2025-07-11
- Primary completion
- 2025-11-01
- Completion
- 2025-11-01
- First posted
- 2025-06-29
- Last updated
- 2025-10-20
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07044271. Inclusion in this directory is not an endorsement.